Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Characterization of patients prescribed with sacubitril/valsartan: a study in the pharmacies
Session:
Posters 3 - Écran 7 - Insuficiência Cardíaca
Speaker:
Marta Afonso-Silva
Congress:
CPC 2019
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.4 Chronic Heart Failure – Treatment
Session Type:
Posters
FP Number:
---
Authors:
Marta Afonso-Silva; Pedro A. Laires; Maria Cary; José Pedro Guerreiro; Mariana Romão; António Teixeira Rodrigues
Abstract
<p><strong>Objectives: </strong>The generation of real world data regarding sacubitril/valsartan (sac/val) is of major importance for regulatory and health technology assessment purposes. The aim of this study is to characterize the clinical and therapeutic profile of the patients prescribed with sac/val in Portugal through community pharmacies.</p> <p><strong>Methods: </strong>The PRiMe study is a cross-sectional and multicenter study. Adult patients (≥18 years) or caregivers with a prescription (initial or refill) of sac/val are being recruited through Portuguese community pharmacies. All community pharmacies associated with the Portuguese National Association of Pharmacies (~2,600) were invited to participate and 418 were enrolled. Sociodemographic data, clinical and therapeutic characteristics, healthcare resource utilization and patient-reported outcomes are being collected directly from the patients or caregivers through a structured two-part questionnaire: 1<sup>st</sup>) delivered by a trained pharmacist; 2<sup>nd</sup>) filled in by the patient. Additional data are being collected through the pharmacy’s software and patient’s echocardiogram report (the last available before sac/val initiation). This study was approved by the competent Ethics Committee and is compliant with the General Data Protection Regulation.</p> <p><strong>Results: </strong>As of Nov 2018, a total of 165 eligible patients (45 new users) were recruited, 26% through their caregiver. The majority of patients were male (64%) with an average of 70 years (range: 35-93). A total of 71% of patients were overweight (body mass index [BMI]> 25 kg/m<sup>2</sup>) with a mean BMI of 28 kg/m<sup>2</sup> (SD=4.4). About 45% were smokers/ex-smokers and 15% of the patients lived alone. The mean time since heart failure (HF) diagnosis was 7.3 years (SD=8.2). The most common comorbidities reported were hypertension (72%), atrial fibrillation (70%) and high cholesterol (56%). About 37% of the patients had an implantable cardiac device. The specialty of the doctor who first prescribed sac/val was cardiology in 82% of the patients. A total of 80% of the patients were taking ACEI or ARB at least one month before starting sac/val. According to the self-assessed NYHA, 85% of the patients were symptomatic (classes II to IV). The majority of patients (50% and 63%) had reduced ejection fraction, ≤35% and ≤40%, respectively.</p> <p><strong>Conclusions: </strong>This study shows that most of the patients prescribed with sac/val have symptomatic chronic HF with reduced ejection fraction and that a great proportion had previous treatment for HF.</p>
Our mission: To reduce the burden of cardiovascular disease
Visit our site
